News
NEPH
2.200
-5.58%
-0.130
Nephros Inc to Present Corporate Strategies at Showcase
TipRanks · 4d ago
Weekly Report: what happened at NEPH last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at NEPH last week (0415-0419)?
Weekly Report · 04/22 11:14
Weekly Report: what happened at NEPH last week (0408-0412)?
Weekly Report · 04/15 11:06
Weekly Report: what happened at NEPH last week (0401-0405)?
Weekly Report · 04/08 11:11
Weekly Report: what happened at NEPH last week (0325-0329)?
Weekly Report · 04/01 11:09
Weekly Report: what happened at NEPH last week (0318-0322)?
Weekly Report · 03/25 11:12
Weekly Report: what happened at NEPH last week (0311-0315)?
Weekly Report · 03/18 11:10
Weekly Report: what happened at NEPH last week (0304-0308)?
Weekly Report · 03/11 11:07
Nephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized Operations
Maxim Group maintains a Buy rating on Nephros. The company is a medical device company that specializes in ultrafiltration. Nephros’s price has increased 65.64% in the past six months. The firm has no debt and a solid cash position.
TipRanks · 03/09 20:25
Nephros Raised to Speculative Buy From Hold by Benchmark
Dow Jones · 03/08 18:56
Nephros Price Target Announced at $5.00/Share by Benchmark
Dow Jones · 03/08 18:56
Benchmark Upgrades Nephros to Speculative Buy, Announces $5 Price Target
Benzinga · 03/08 18:46
Nephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy Rating
Analyst Robert Wasserman of Benchmark Co. Maintained a Buy rating on Nephros (NEPH – Research Report), with a price target of $5.00. The company showed a strong financial performance with a year-over-year revenue increase of 43% to $14.2 million.
TipRanks · 03/08 16:15
Nephros Inc reports results for the quarter ended in December - Earnings Summary
Nephros Inc reports results for the quarter ended in December. Revenue rose 27.2% to $3.25 million from a year ago. Nephros Inc shares had fallen by 10.4% this quarter. The company reported a quarterly adjusted loss of 6 cents per share.
Reuters · 03/08 04:25
NEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023
Nephros reported earnings per share of -6 cents. The company reported revenue of $3.30 million. This was 13.39% worse than the analyst estimate for revenue in the same quarter. The stock was down 2.7% in after-hours trading.
Investorplace · 03/08 02:51
Nephros reports Q4 results
Seeking Alpha · 03/07 21:28
Earnings Scheduled For March 7, 2024
CI&T is expected to report quarterly earnings at $0.06 per share on revenue of $106.08 million. Other companies expected to release earnings before the bell include Burlington Stores, American Eagle Outfitters and Bilibili. The companies will also be reporting earnings for their third quarter.
Benzinga · 03/07 09:49
Weekly Report: what happened at NEPH last week (0226-0301)?
Weekly Report · 03/04 11:09
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
Nephros, Inc. Will file its fourth quarter and fiscal year financial results on March 7, 2024 after market close. The company will host a conference call that same day. Nephros is a leading water technology company providing filtration solutions to the medical and commercial markets.
Barchart · 02/29 15:30
More
Webull provides a variety of real-time NEPH stock news. You can receive the latest news about Nephros Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEPH
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. It operates through the Water Filtration segment. In the medical markets, it sells water filtration products. In the commercial markets, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Its products are marketed primarily to the food service, hospitality, convenience store, and health care markets. These commercial products are also marketed into medical markets, as supplemental filtration to its medical filters. The Company’s filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.